Analysis of the risk of long-term stroke in patients with hepatocellular carcinoma treated with immune-targeted combination therapy        YANG Kun* , LONG Yun-xiang , LIU Tong ,et al. *Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China；School of the Future Technology, Xi’an Jiaotong University,Xi’an 710049,China
Corresponding authors: QU Kai, E-mail: joanne8601@163.com; LI Guo-liang, E-mail: liguoliang_med@163.com; LIU Chang, E-mail: eyrechang@126.com 
Abstract    Objective    To analyze the risk of long-term stroke during immunotherapy combined with targeted therapy in patients with primary liver cancer. Methods    The clinical data of 134 patients with primary hepatocellular carcinoma in the Department of Hepatobiliary Surgery of the First Affiliated Hospital of Xi'an Jiaotong University from January 2016 to December 2018 were retrospectively analyzed. Univariate and multivariate Cox regression was used to screen out the related risk factors for long-term stroke in patients with primary liver cancer, and propensity score matching was used to match independent risk factors and factors that differed between groups, Kaplan-Meier method was used to estimate the incidence of stroke among the target risk factors, and survival curves were plotted and statistically tested. Results  Multivariate Cox regression analysis showed that age and immunotherapy combined with targeted therapy were independent risk factors for long-term stroke in patients with liver cancer (P < 0.05). Kaplan-Meier prognostic analysis showed that immunotherapy combined with targeted therapy was an important risk factor for long-term stroke in patients with primary hepatocellular carcinoma before and after matching; the hazard ratio was 9.1 before matching and 11.8 after matching (all P<0.05). Conclusion    Immunotherapy combined with targeted therapy increases the risk of long-term stroke in primary hepatocellular carcinoma patients.